Axel U Dignass (Axel Dignass, A Dignass)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 41

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

United European gastroenterology journal

Scandinavian journal of gastroenterology

Medicina (Kaunas, Lithuania)

This page only lists publications with an associated author ORCID identifier.

Publications

Nuh N Rahbari, Sebastiano Biondo, Ricardo Frago, Manuel Feißt, Esther Kreisler, Inga Rossion, Monica Serrano, Dirk Jäger, Monika Lehmann, Florian Sommer, Axel U Dignass, Claus Bolling, Ilka Vogel, Ulrich Bork, Markus W Büchler, Gunnar Folprecht, Meinhard Kieser, Florian Lordick, Jürgen Weitz, null null
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Nuh N Rahbari, Sebastiano Biondo, Ricardo Frago, Manuel Feißt, Esther Kreisler, Inga Rossion, Monica Serrano, Dirk Jäger, Monika Lehmann, Florian Sommer, Axel U Dignass, Claus Bolling, Ilka Vogel, Ulrich Bork, Markus W Büchler, Gunnar Folprecht, Meinhard Kieser, Florian Lordick, Jürgen Weitz, null null
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (13) (2024)
Fernando Magro, Paula Leão Moreira, Gaia Catalano, Catarina Alves, Fernando Magro, Maria Manuela Estevinho, Isabel Silva, Axel U Dignass, Laurent Peyrin Biroulet, Silvio Danese, Vipul Jairath, Claudia Camila Dias, Mafalda Santiago
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis. United European gastroenterology journal (2023)
Alessandro Armuzzi, Ailsa L Hart, Joseph Christopher Cappelleri, Nadir Mammar, Peter Hur, Benjamin Hoskin, Fritha Hennessy, Gary Milligan, Axel U Dignass
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC gastroenterology 23 (1) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Philip J Smith, Mathurin Fumery, Rupert W L Leong, Kerri L Novak, Axel U Dignass
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert review of clinical immunology (2023)
Axel U Dignass, Stefan Rath, Thomas Kleindienst, Andreas Stallmach
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply. Alimentary pharmacology & therapeutics 58 (6) (2023)
Alessandro Armuzzi, Ailsa L Hart, Joseph Christopher Cappelleri, Nadir Mammar, Peter Hur, Benjamin Hoskin, Fritha Hennessy, Gary Milligan, Axel U Dignass
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC gastroenterology 23 (1) (2023)
Axel U Dignass, Stefan Rath, Thomas Kleindienst, Andreas Stallmach
Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges. Alimentary pharmacology & therapeutics (2023)
Laurent Peyrin Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel U Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Frederic Lavie, Marco Daperno, Milan Lukáš, Alessandro Armuzzi, Mark Löwenberg, Daniel R Gaya, Silvio Danese
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST. Alimentary pharmacology & therapeutics (2023)
Julian Panes, Severine Vermeire, Geert R D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Daniel R Gaya, Laurent Peyrin Biroulet, Axel U Dignass, null null
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial. United European gastroenterology journal (2023)
Alessandro Armuzzi, Ailsa L Hart, Joseph Christopher Cappelleri, Nadir Mammar, Peter Hur, Benjamin Hoskin, Fritha Hennessy, Gary Milligan, Axel U Dignass
Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. BMC gastroenterology 23 (1) (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Bénédicte Caron, Vipul Jairath, Ferdinando D'Amico, Sameer Al Awadhi, Axel U Dignass, Ailsa L Hart, Taku Kobayashi, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Kristine Paridaens, Silvio Danese, Laurent Peyrin-Biroulet
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. Medicina (Kaunas, Lithuania) 59 (1) (2023)
Ferdinando D'Amico, Fernando Magro, Benedicte Caron, Axel U Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. Journal of clinical medicine 12 (3) (2023)
Bélène Podmore, Dominik Beier, Johan Burisch, Elisabeth Genestin, Dennis Haeckl, Oliver Nagel, Nawab Qizilbash, David A Schwartz, Stephan R Vavricka, Dimitri Bennett, Axel U Dignass
Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study. United European gastroenterology journal (2023)
Aditya Sardesai, Axel U Dignass, Peter Quon, Sandra Milev, Joseph Christopher Cappelleri, Agnes Kisser, Irene Modesto, Puza P Sharma
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. Journal of medical economics 24 (1) (2021)
Ayşegül Aksan, Axel U Dignass, Jürgen Michael Stein
Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert review of hematology (2021)
Axel U Dignass, Kristine Paridaens, Sameer Al Awadhi, Jacob Begun, Jae Hee Cheon, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grażyna Rydzewska, Simon P L Travis
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian journal of gastroenterology 57 (4) (2021)
Raf Bisschops, Matthew D Rutter, Miguel Areia, null Cristiano Spada, Dirk Domagk, Michel F Kaminski, Andrew Veitch, Wafaa Khanoussi, Ian M Gralnek, Cesare Hassan, Helmut Messmann, Thierry Ponchon, Paul Fockens, Axel U Dignass, Mario Dinis-Ribeiro
Overcoming the barriers to dissemination and implementation of quality measures for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) position statement. United European gastroenterology journal 9 (1) (2021)
Axel U Dignass, John Waller, Joseph C Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Melanie May, Berit Libutzki, Danielle Bargo
Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. Journal of medical economics 23 (4) (2020)
HoUng Kim, Rieke E Alten, Luisa Avedano, Axel U Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M Irving, Prof Jørgen Jahnsen, Péter L Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven R A Simoens, René Westhovens, Silvio Danese, Ji Hoon Jeong
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80 (2) (2020)
Wolfgang Alexander Seeger, Juliane Thieringer, Philip Esters, Benjamin Allmendinger, Jürgen Michael Stein, Hermann Schulze, Axel U Dignass
Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease. United European gastroenterology journal 8 (7) (2020)
Silvio Danese, Ailsa Hart, Axel U Dignass, Gionata Fiorino, Edouard Louis, Stefanos Bonovas, Geert D'Haens, Iris Dotan, Gerhard Rogler, Kristine Paridaens, Laurent Peyrin-Biroulet
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United European gastroenterology journal 7 (9) (2019)
Axel U Dignass, Britta Siegmund, Ralf Goertz, Gundula Schneidewind, Lena Fanter
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. Scandinavian journal of gastroenterology 54 (2) (2019)
Ayşegül Aksan, Axel U Dignass, Jürgen Michael Stein
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in therapy 36 (8) (2019)
Florian Rieders, D Bettenworth, C Ma, C E Parker, L A Williamson, S A Nelson, G van Assche, Antonio Di Sabatino, Y Bouhnik, Ryan William Stidham, Axel U Dignass, G Rogler, S A Taylor, J Stoker, J Rimola, M E Baker, J G Fletcher, J Panes, William J Sandborn, Brian G Feagan, V Jairath
An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Alimentary pharmacology & therapeutics 48 (3) (2018)
Jürgen Michael Stein, Andreas Walper, Wolfgang Klemm, Karima Farrag, Ayşegül Aksan, Axel U Dignass
Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scandinavian journal of gastroenterology 53 (9) (2018)
Axel U Dignass, Ayesha Akbar, Daniel C Baumgart, Gilles Bommelaer, Guillaume Bouguen, Guillaume Cadiot, Anton Gillessen, Jean-Charles Grimaud, Ailsa Hart, Syed Hoque, Richard Makins, Christophe Michiels, Jacques Moreau, Purushothaman Premchand, Wolfgang Ramlow, Stefan Schanz, Sreedhar Subramanian, Christian von Tirpitz, Bruno Bonaz
Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scandinavian journal of gastroenterology 53 (4) (2018)
Hermann Schulze, Philip Esters, Franz Hartmann, Jürgen Michael Stein, Christina Christ, Michael Zorn, Axel U Dignass
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scandinavian journal of gastroenterology 53 (6) (2018)
Axel U Dignass, Karima Farrag, Jürgen Michael Stein
Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. International journal of chronic diseases 2018 (2018)
Laurent Peyrin Biroulet, Anthony Lopez, J R Fraser Cummings, Axel U Dignass, Trond Espen Detlie, Silvio Danese
Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Alimentary pharmacology & therapeutics 48 (6) (2018)
Ayşegül Aksan, H Işık, Heinfried H Radeke, Axel U Dignass, Jürgen Michael Stein
Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 45 (10) (2017)
Jürgen Michael Stein, Ayşegül Aksan, Karima Farrag, Axel U Dignass, Heinfried H Radeke
Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert opinion on pharmacotherapy 18 (16) (2017)
Ayşegül Aksan, H Işık, Heinfried H Radeke, Axel U Dignass, Jürgen Michael Stein
Editorial: which iron preparation for patients with IBD? Authors' reply. Alimentary pharmacology & therapeutics 46 (2) (2017)
Ayşegül Aksan, H Işık, Heinfried H Radeke, Axel U Dignass, Jürgen Michael Stein
Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies-authors' reply. Alimentary pharmacology & therapeutics 46 (7) (2017)
Ayşegül Aksan, H Işık, Heinfried H Radeke, Axel U Dignass, Jürgen Michael Stein
Letter: inconsistency in reporting of hypophosphataemia after intravenous iron-authors' reply. Alimentary pharmacology & therapeutics 46 (6) (2017)
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B Gecse, Axel U Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Peter L Lakatos, Valentin Brodszky
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert review of pharmacoeconomics & outcomes research 17 (6) (2017)